| 32nd week of 2012 patent applcation highlights part 42 |
| Patent application number | Title | Published |
|---|
| 20120202693 | SYNERGISTIC HERBICIDAL COMPOSITION CONTAINING PENOXSULAM AND GLYPHOSATE - A synergistic mixture of penoxsulam and glyphosate controls weeds in crops, especially vines, range and pasture, industrial vegetation management, rights of way and in any glyphosate tolerant crop. | 2012-08-09 |
| 20120202694 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE - The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments. | 2012-08-09 |
| 20120202695 | CORE STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF - The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within a metal oxide shell, processes for their preparations, comparisons comprising them and uses thereof. | 2012-08-09 |
| 20120202696 | OPEN-STRUCTURE MAGNETIC ASSEMBLY FOR MAGNETIC RESONANCE IMAGING - An open-structure magnetic assembly is adapted to generate a homogeneous magnetic field in an accessible space region, including a first and second independent source of magnetic field ( | 2012-08-09 |
| 20120202697 | STIFFENED GRADIENT COIL - In a cylindrical superconducting magnet system for magnetic resonance imaging, primary superconducting coils are positioned within an outer vacuum chamber. A thermal radiation shield surrounds the primary superconducting coils. A gradient coil assembly is axially aligned with the primary superconducting coils. A mechanical support assembly is radially positioned outside of the primary superconducting coils and is mechanically attached to the gradient coil assembly by mechanical attachments which pass through through-holes through the outer vacuum chamber and the thermal radiation shield. | 2012-08-09 |
| 20120202698 | HIGH THROUGHPUT DETECTION OF MOLECULAR MARKERS BASED ON AFLP AND HIGH THROUGH-PUT SEQUENCING - The present invention relates to a high throughput method for the identification and detection of molecular markers wherein restriction fragments are generated and suitable adaptors comprising (sample-specific) identifiers are ligated. The adapter-ligated restriction fragments may be selectively amplified with adaptor compatible primers carrying selective nucleotides at their 3′ end. The amplified adapter-ligated restriction fragments are, at least partly, sequenced using high throughput sequencing methods and the sequence parts of the restriction fragments together with the sample-specific identifiers serve as molecular marker. | 2012-08-09 |
| 20120202699 | Method For The Determination Of Intra- And Intermolecular Interactions In Aqueous Solution - The present invention relates to the determination of intra- or intermolecular interaction between molecules in aqueous solution, the method comprising the steps of: (a) determining the dehydration of all atoms in the intermolecular interface, (b) adding the vacuum hydrogen bond energy, and (c) further adding the change in the free enthalpy of the interacting partners upon their interaction. The obtained results can be used for the prediction if and to what extent two molecules of various origin fit to each other. | 2012-08-09 |
| 20120202700 | Sample preparation and detection method - A method for detecting a biological agent in a liquid sample is disclosed. The method comprises: passing a liquid sample through a filter in the presence of a surfactant; and subjecting the filtered sample to direct polymerase chain reaction (PCR) analysis for the presence of a biological agent, wherein the filter has a porosity that allows the biological agent to pass through the filter in its intact form. | 2012-08-09 |
| 20120202701 | AN ANTIBODY-GLYCAN COMPLEX TARGETING THE DISIALYL CORE II AND SIALYL LEWIS X STRUCTURES, AND USES THEREOF INVOLVING ANALYSIS OF STEM CELLS OR CANCER CELLS - Antibody-saccharide-complexes and methods and uses related to analysis of cells. Also disclosed is a method of selection of new antibody with CHO-specificity and to a use of antibodies produced for the analysis of stem cells or cancer cells or other cells or tissues known to bind to CHO-antibodies. | 2012-08-09 |
| 20120202702 | DETECTION OF LOW CONCENTRATION BIOLOGICAL AGENTS - Provided are methods of preparing a sample for detection by placing the sample on a shrinkable scaffold and then shrinking the scaffold. An exemplary shrinkable scaffold is a thermoplastic substrate. | 2012-08-09 |
| 20120202703 | METHOD FOR DETECTING AND QUANTIFYING A TARGET SUBSTANCE USING A BIOCHIP - The present invention relates to a method for detecting and quantifying a target substance using a biochip having a substrate onto which probe molecules are fixed, and more particularly, to a method for detecting and quantifying a target substance with the naked eye by using a biochip, comprising the steps of preparing a biochip having a substrate onto which probe molecules are fixed, contacting the biochip with a sample containing a target substance having electric charges, reacting the target substance with nanoparticles having electric charges that are opposite to those of the target substance, and then reacting with a metal enhancing solution so as to amplify the size of the nanoparticles. | 2012-08-09 |
| 20120202704 | MULTI-SAMPLE INDEXING FOR MULTIPLEX GENOTYPING - A method for determining the presence of multiple nucleotide sequences of interest in multiple samples while preserving the identity of each sample, by contacting the samples with a plurality of probe sets. The probes are designed to indicate the presence of the sequences of interest and the identity of the sample containing the sequence of interest in complex mixtures. Applications of the method include genotyping, expression analysis, and identification of individual species in complex samples. Kits of probe sets for use in the methods are also provided. | 2012-08-09 |
| 20120202705 | ACUTE KIDNEY INJURY RISK TESTING - The present invention relates to the method of determining the risk of acute kidney injury comprising determining the amount of one or more marker(s) selected from REN, SLC38A4, IL17RB, TMEM149, FLRT3, and CATSPERG or any combination thereof in a sample. | 2012-08-09 |
| 20120202706 | 6-0-SULFATED POLYSACCHARIDES AND METHODS OF PREPARATION THEREOF - Disclosed are methods of 6-O sulfating glucosaminyl N-acetylglucosamine residues (GlcNAc) in a polysaccharide preparation and methods of converting anticoagulant-inactive heparan sulfate to anticoagulant-active heparan sulfate and substantially pure polysaccharide preparations made by such methods. Also disclosed is a mutant CHO cell which hyper-produces anticoagulant-active heparan sulfate. Methods for elucidating the sequence of activity of enzymes in a biosynthetic pathway are provided. | 2012-08-09 |
| 20120202707 | CELL LINES USEFUL FOR ASSESSING MODULATION OF AUTOPHAGY - Methods for screening for modulators of autophagy are disclosed. Methods for identifying genes whose expression inhibits autophagy, as well as genes whose expression promotes autophagy, are disclosed. Also disclosed are methods for identifying compounds that stimulate autophagy, as well as compounds that inhibit autophagy. Cell lines that may be used in the methods of identification are also disclosed. | 2012-08-09 |
| 20120202708 | COMPLEMENT FACTOR H COPY NUMBER VARIANTS FOUND IN THE RCA LOCUS - Provided herein is a variant in the RCA locus and methods for detecting the presence, absence or amount of multiple forms of the variant. | 2012-08-09 |
| 20120202709 | Devices and Methods for Producing and Analyzing Microarrays - Devices and methods for producing and analyzing microarrays are disclosed. In an embodiment, a method for converting a library of beads to an array of analytes includes positioning a plurality of beads having one or more analytes bound therein on a solid support in a spatially separated manner, causing the analytes to be released from the plurality of microparticles, and localizing the released analytes in discrete spots. | 2012-08-09 |
| 20120202710 | Methods and compositions for generation of germline human antibody genes - The present invention relates to a method for in vitro producing polynucleotides encoding human germline antibody V-regions. Also disclosed is a library of human germline antibody V-region genes. | 2012-08-09 |
| 20120202711 | NOVEL IMINECALIXARENE DERIVATIVES AND AMINOCALIXARENE DERIVATIVES, METHOD OF PREPARATION THEREOF, AND SELF-ASSEMBLED MONOLAYER PREPARED BY THE METHOD, FIXING METHOD OF OLIGO-DNA BY USING THE SELF-ASSEMBLED MONOLAYER, AND OLIGO-DNA CHIP PREPARED BY THE METHOD - The present invention relates to novel iminecalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA by using the self-assembled monolayer, and oligo-DNA chip prepared by the method. Also, the present invention relates to novel aminocalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA wherein the oligo-DNA is voluntarily fixed by molecular recognition on said self-assembled monolayer in a liquid phase, and oligo-DNA chip prepared by the method. | 2012-08-09 |
| 20120202712 | Compositions, Methods and Related Uses for Cleaving Modified DNA - Compositions, methods and related uses are provided relating to cleaving modified DNA. For example, a set of DNA fragments obtainable by enzymatic cleavage of a large DNA is described where at least 50% are similarly sized and have a centrally positioned modified nucleotide. In addition, an enzyme preparation is provided that includes one or more enzymes that recognize a modified nucleotide in a DNA and cleave the DNA at a site that is at a non-random distance from the modified nucleotide. The one or more enzymes are further characterized by an N-terminal conserved domain with greater than 90% amino acid sequence homology to WXD(X) | 2012-08-09 |
| 20120202713 | CONSTRUCTS AND LIBRARIES COMPRISING ANTIBODY SURROGATE LIGHT CHAIN SEQUENCES - The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same. | 2012-08-09 |
| 20120202714 | CONJUGATE PROBES AND OPTICAL DETECTION OF ANALYTES - This invention relates to conjugate probes and optical detection of analytes. More specifically, this invention relates to conjugate probes which are used to form an array for a biosensor employing optical detection of analytes. | 2012-08-09 |
| 20120202715 | TISSUE DISSAGGREGATOR DEVICE AND METHODS OF USING THE SAME - The tissue disaggregator device includes a base having a multiple well array. Each of the wells includes a screen embedded into bottom portion of the well. The device removably connects with standardized plate and allows for multiple fold increase in tissue sample preparation. | 2012-08-09 |
| 20120202716 | Construction of diverse synthetic peptide and polypeptide libraries - The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for generating sequence diversity by directed multisyntheses oligonucleotide synthesis. The present methods enable the reduction of large complex annotated databases to simpler datasets of related sequences, based upon relevant single or multiple key parameters that can be individually directly defined. The methods further enable the creation of diverse libraries based on this approach, using multisynthetic collections of discrete and degenerate oligonucleotides to capture the diverse collection of sequences, or portions thereof. | 2012-08-09 |
| 20120202717 | APPLICATION OF DEGRADABLE FIBERS IN INVERT EMULSION FLUIDS FOR FLUID LOSS CONTROL - A method of treating a subterranean formation including emplacing in a wellbore a fluid, comprising an oleaginous continuous phase, a non-oleaginous discontinuous phase, an emulsifier, at least one degradable material, and at least one bridging material, and contacting the formation with the fluid. A method and apparatus related to an invert emulsion fluid loss pill including an oleaginous continuous phase, a non-oleaginous discontinuous phase, an emulsifier, at least one degradable material, wherein the degradable material hydrolyzes to release an organic acid, and at least one bridging material. | 2012-08-09 |
| 20120202718 | PRECIPITATED WEIGHTING AGENTS FOR USE IN WELLBORE FLUIDS - A method of formulating a wellbore fluid that includes precipitating a weighting agent from a solution; and adding the precipitated weighting agent to a base fluid to form a wellbore fluid is disclosed. Fluids and methods of formulating wellbore fluids that contain dispersant coated precipitated weighting agents are also disclosed. | 2012-08-09 |
| 20120202719 | THERMOSET NANOCOMPOSITE PARTICLES, PROCESSING FOR THEIR PRODUCTION, AND THEIR USE IN OIL AND NATURAL GAS DRILLING APPLICATIONS - Use of two different methods, either each by itself or in combination, to enhance the stiffness, strength, maximum possible use temperature, and environmental resistance of such particles is disclosed. One method is the application of post-polymerization process steps (and especially heat treatment) to advance the curing reaction and to thus obtain a more densely crosslinked polymer network. The other method is the incorporation of nanofillers, resulting in a heterogeneous “nanocomposite” morphology. Nanofiller incorporation and post-polymerization heat treatment can also be combined to obtain the benefits of both methods simultaneously. The present invention relates to the development of thermoset nanocomposite particles. Optional further improvement of the heat resistance and environmental resistance of said particles via post-polymerization heat treatment; processes for the manufacture of said particles; and use of said particles in the construction, drilling, completion and/or fracture stimulation of oil and natural gas wells are described. | 2012-08-09 |
| 20120202720 | ENVIRONMENTALLY FRIENDLY STIMULATION FLUIDS, PROCESSES TO CREATE WORMHOLES IN CARBONATE RESERVOIRS, AND PROCESSES TO REMOVE WELLBORE DAMAGE IN CARBONATE RESERVOIRS - The present invention includes processes to create wormholes in carbonate reservoirs by contacting a formation with a solution comprising glutamic acid N,N-diacetic acid (GLDA) and/or a salt thereof, methylglycine-N,N-diacetic acid (MGDA) and/or a salt thereof, or a combination thereof. The present invention also includes processes to remove wellbore damage in a carbonate reservoir by contacting a damaged zone of the carbonate reservoir with a solution comprising GLDA and/or a salt thereof, methylglycine-N,N-diacetic acid (MGDA) and/or a salt thereof, or a combination thereof. The present invention further includes solutions comprising a salt and further comprising GLDA and/or a salt thereof, methylglycine-N,N-diacetic acid (MGDA) and/or a salt thereof, or a combination thereof. | 2012-08-09 |
| 20120202721 | ELECTROLYZED WATER - AMINE COMPOSITIONS AND METHODS OF USE - The invention is directed to a treatment fluid comprising electrolyzed water and an amine, and methods for producing and using same in the treatment of a gas or liquid containing a contaminant such as an acid gas or a sulphur compound. | 2012-08-09 |
| 20120202722 | CONCENTRATE FOR PRODUCING A COOLING AND RELEASE AGENT OR A COOLING AND LUBRICATING AGENT AND SUCH COOLING AND RELEASE AGENTS AND COOLING AND LUBRICATING AGENTS - A concentrate for producing a cooling and release agent for reusable casting dies such as a steel casting die, or a cooling and lubricating agent for machining with an active substance dissolved in water. The concentrate comprises 10 to 50 wt.-% of a protein based on the weight of the concentrate. | 2012-08-09 |
| 20120202723 | POLYOLS AND THEIR USE IN HYDROCARBON LUBRICATING AND DRILLING FLUIDS - Polyhydroxyl functional compounds that contain an all hydrocarbon backbone, wherein all of the hydroxyl groups are bonded to a primary carbon atom, are prepared through the reaction of an alpha, omega-terminal diol having a total of from about 6 to about 42 carbon atoms terminated with a mono-ol having a total of from about 4 to about 42 carbon atoms. The polyols can be used as additives in hydrocarbon oils, drilling fluids, industrial and automotive lubricating fluids, dispersants, engine lubricants, greases, coatings, adhesives, and also in magnetorheological fluids to improve various properties such as dispersion, wear protection, reduction of friction, high temperature stability, and improved aging. | 2012-08-09 |
| 20120202724 | METHOD OF USING IONIC LIQUIDS TO IMPROVE THE LUBRICATION OF CHAINS, STEEL BELTS, WHEEL BEARINGS, ROLLER BEARINGS, AND ELECTRIC MOTORS - A method in which an improved lubricating composition containing ionic liquids is used to enable operation of chains, steel belts, wheel bearings, roller bearings, sliding bearings and electric motors for at least 48 hours by reducing the evaporation loss and the lackification tendency of the lubricant due to the lubricant being protected against thermal and oxidative attack. | 2012-08-09 |
| 20120202725 | 2,5-FURAN DICARBOXYLATES COMPRISING ISODECANOLS, AND USE THEREOF - The invention relates to mixtures of isodecyl furan-2,5-dicarboxylate of formula I, methods for producing said mixtures of isodecyl furan-2,5-dicarboxylate of formula I, compositions containing mixtures of isodecyl furan-2,5-dicarboxylate of formula I, uses of the mixtures of isodecyl furan-2,5-dicarboxylate of formula I as plasticizers, and uses of the aforementioned compositions containing isodecyl furan-2,5-dicarboxylate of formula I. | 2012-08-09 |
| 20120202726 | Lubricating Composition Containing an Antiwear Agent - The invention provides a lubricating composition containing an oil of lubricating viscosity and a compound obtained/obtainable by a process comprising reacting a glycolic acid, a 2-halo-acetic acid, or a lactic acid, or an alkali or alkaline metal salts thereof, (typically glycolic acid or a 2-halo-acetic acid) with at least one member selected from the group consisting of an amine, an alcohol, and an aminoalcohol. The invention further relates to the use of the lubricating composition in an internal combustion engine. | 2012-08-09 |
| 20120202727 | Antiwear Composition and Method of Lubricating an Internal Combustion Engine - The present invention relates to a lubricating composition containing an oil of lubricating viscosity and an antiwear package. The antiwear package may contain a derivative of a hydroxycarboxylic acid; and a salt of a sulphur-free phosphorus-containing compound. The salt includes amine salts, ammonium salts, metal salts and mixtures thereof. The invention further provides for a method of supplying an internal combustion engine with the lubricating composition. | 2012-08-09 |
| 20120202728 | LUBRICATING COMPOSITION - The present invention provides a lubricating composition comprising:—a base Oil;—a detergent; and—an amine compound having the following general formula (I): R 1 NHR 2 (I) wherein R1 represents a hydrocarbyl group containing 1 to 50 carbon atoms and R2 is selected from the group consisting of H and a hydrocarbyl group containing 1 to 50 carbon atoms; wherein the amine compound is present at a level of greater than 0.3 wt % by weight of the lubricating composition. | 2012-08-09 |
| 20120202729 | GRAFFITI-CLEANING COMPOSITION - The present invention relates to a composition for cleaning graffiti, including a diester compound and surfactants. | 2012-08-09 |
| 20120202730 | ABRASIVE AGENT BASED ON NATURAL RAW INGREDIENTS, HAVING PROPERTIES IMPROVING RHEOLOGY - The invention relates to flours of plant components, wherein a solution of 10 ml water and 1 ml of an aqueous methylene blue solution of 0.1 wt % brought into contact with 1 g of the flour, comprising an extinction at a wavelength of 660 nm to <1, to a method for producing said flours, products comprising said flours, and the use of the flours for producing skin and hand cleaning agents, surface cleansers, or peeling agents, and the use of the products for cleaning skin, hands, and surfaces. | 2012-08-09 |
| 20120202731 | PROCESS FOR THE PREPARATION OF A POWDER COMPRISING ONE OR MORE COMPLEXING AGENT SALTS - A process is proposed for the preparation of a powder comprising one or more complexing agent salts of the general formula | 2012-08-09 |
| 20120202732 | MODIFIED AAV CAPSID POLYPEPTIDES - The present invention is concerned with the provision of a polynucleotide encoding an AAV capsid polypeptide comprising an inserted peptide and a vector comprising said polynucleotide. Moreover, contemplated is a host cell comprising said polynucleotide or vector, a method for the manufacture of said capsid polypeptide as well as said polypeptide. Further included is an antibody specifically binding to said polypeptide and a medicament comprising said polynucleotide, vector, polypeptide, or antibody. Also contemplated are the use of said polynucleotide, vector, polypeptide, or antibody for the manufacture of a medicament for the treatment of vascular disease and a method for the identification of a compound binding to said polypeptide. | 2012-08-09 |
| 20120202733 | INHIBITION OF TREM RECEPTOR SIGNALING WITH PEPTIDE VARIANTS - Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices). | 2012-08-09 |
| 20120202734 | ANTIBIOTIC, ITS NUCLEOTIDE SEQUENCE, METHODS OF CONSTRUCTION AND USES THEREOF - The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the | 2012-08-09 |
| 20120202735 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 2012-08-09 |
| 20120202736 | SPRAY-DRIED COLLECTIN COMPOSITIONS AND PROCESS FOR PREPARING THE SAME - The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria, fungi, and parasites. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds. | 2012-08-09 |
| 20120202737 | New bacitracin antibiotics - The invention concerns new Bacitracin compounds containing methylene-isoleucine. | 2012-08-09 |
| 20120202738 | THERAPY FOR ENTERIC INFECTIONS - There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment. | 2012-08-09 |
| 20120202739 | GDF3 ANTIBODIES AND RELATED METHODS - In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3. | 2012-08-09 |
| 20120202740 | SCGB3A2 AS A GROWTH FACTOR AND ANTI-APOPTOTIC AGENT - The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents. | 2012-08-09 |
| 20120202741 | DELIVERY OF BMP-7 AND METHODS OF USE THEREOF - The present invention generally relates to delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist and methods of use thereof. In some embodiments, methods and devices are provided for delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist to a patient. In some cases, the BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be released in controlled fashion from a device in fluid communication with a patient. In some embodiments, the BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be expressed by cells within a device. In other embodiments, methods are provided for improving the function of devices containing renal proximal tubule cells. For example, in some embodiments, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be used to inhibit disruption of cell layers comprising renal proximal tubule cells. In another embodiment, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be used to inhibit trans- and de-differentiation of renal proximal tubule cells. In another embodiment, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be used to improve renal proximal tubule cell functions. | 2012-08-09 |
| 20120202742 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 2012-08-09 |
| 20120202743 | SUSTAINED RELEASE FORMULATIONS COMPRISING GnRH ANALOGUES - The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogues thereof and the manufacturing process of such pharmaceutical compositions. | 2012-08-09 |
| 20120202744 | DUAL ANTAGONISM OF ENDOTHELIN TYPE A AND BRADYKININ B1 RECEPTORS FOR TREATING PAIN AND PREVENTING CARTILAGE DEGRADATION - The present invention relates to the field of anatomy, and more particularly to the control of pain and to the prevention and treatment of osteoarthritic cartilage degradation. Described herein are methods for treating pain which comprise administering to a subject in need a combination of (i) an antagonist of the endothelin type A receptor (ETA) and (ii) an antagonist of the bradykinin B1 receptor (BKB1). Also described are methods for preventing osteoarthritic cartilage degradation and pharmaceutical compositions for treating pain, for preventing osteoarthritic cartilage degradation, and/or for preventing osteoarthritic joint inflammation, in subjects. | 2012-08-09 |
| 20120202745 | ADULT CEREBELLUM-DERIVED NEURAL STEM CELLS AND COMPOSITIONS AND METHODS FOR PRODUCING OLIGODENDROCYTES - This disclosure describes a novel population of cerebellum-derived neural stem cells that can be isolated from the adult brain, expanded, and differentiated into neurons, astrocytes and oligodendrocytes. This disclosure also describes compositions and methods for producing oligodendrocytes. Oligodendrocytes can be produced in vitro (e.g., in culture) or in vivo (e.g., for therapy or in a non-human transgenic animal) using the compositions and methods described herein. | 2012-08-09 |
| 20120202746 | DAPTOMYCIN FOR MULTIPLE SCLEROSIS - Compounds and compositions, and methods of use thereof, for treatment and/or prevention of multiple sclerosis, including symptoms associated with multiple sclerosis, and/or treatment and/or prevention of other disease/disorder affecting the nervous system (e.g. central, peripheral) or muscle including symptoms thereof, comprising administering to a subject in need thereof daptomycin and/or daptomycin-related lipopeptide. | 2012-08-09 |
| 20120202747 | PHARMACEUTICAL COMPOSITION, FOOD OR DRINK, AND METHODS RELATED THERETO - A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes. | 2012-08-09 |
| 20120202748 | RECOMBINANT MUSSEL ADHESIVE PROTEIN FP-131 - The present invention relates to a bio-adhesive derived from mussel. In particular, it relates to a recombinant protein fp(foot protein)-131 that is a hybrid of fp-3 variant A and fp-1. According to the present invention, the recombinant protein with adhesive activity can be economically produced in large scale to be used in place of chemical adhesives. | 2012-08-09 |
| 20120202749 | SECRETED FRIZZLED RELATED PROTEIN, SFRP, FRAGMENTS AND METHODS OF USE THEREOF - The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants. | 2012-08-09 |
| 20120202750 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: | 2012-08-09 |
| 20120202751 | METHODS OF MONITORING ENDOPLASMIC RETICULUM (ER) STRESS RESPONSE - Transgenic mammals, cells derived from the animals, and methods of using these to monitor the endoplasmic reticulum (ER) stress response are provided. In some embodiments, the methods allow for monitoring the ER stress response in real time. Some of the methods allow non-invasive in vivo visualization of ER stress response. Also provided are methods of screening molecules and/or treatment conditions for the ability to modulate the ER stress response, methods of treating diseases characterized by ER stress response activity, and methods of detecting the toxicity or therapeutic ratio of molecules that modulate the ER stress response. | 2012-08-09 |
| 20120202752 | Antisense Oligonucleotides - Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is directed to antisense oligonucleotide molecules, pharmaceutical compositions and formulations comprising antisense oligonucleotide molecules, and methods of treating muscular dystrophy related diseases and disorders wherein the antisense oligonucleotide molecules comprises a base sequence selected from the group consisting of SEQ ID NO: 5-8, 10, 12, 14, 16, 24, 27, 28, 34, 35, 37, 40, 42, 44-46, 79, 97, 100, 101, and 116, and combinations thereof. | 2012-08-09 |
| 20120202753 | INHIBITING INFLAMMATION WITH MILK OLIGOSACCHARIDES - A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed. | 2012-08-09 |
| 20120202754 | ENHANCED SUBSTRATES FOR THE PROTEASE ACTIVITY OF SEROTYPE A BOTULINUM NEUROTOXIN - Substrates of botulinum toxin serotype A (BoNT A), kits comprising the substrates, and methods of using the substrates are disclosed. BoNT A cleaves SNAP-25 and the substrates that are based upon a portion of SNAP-25. Various amino acid modifications to the sequence of the peptide based on SNAP-25 are performed. Fluorescence labels that act as donors and acceptors may be added to the substrate to aid in the study of BoNT A. | 2012-08-09 |
| 20120202755 | FOLIAMANGIFEROSIDES, PREPARATION METHOD AND USE THEREOF - Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of α-glucosidase are also disclosed. | 2012-08-09 |
| 20120202756 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS - The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics. | 2012-08-09 |
| 20120202757 | ANTIHYPERTENSIVE COMPOSITION CONTAINING A GINSENOSIDE-ENRICHED FRACTION - The present invention related to an antihypertensive composition containing a fraction enriched with ginsenosides of ginseng. The composition according to the present invention increases the production of nitric oxide through the activation of nitric oxide synthase, and thus exhibits superior antihypertensive effects through the vasodilatory activity. Consequently, the composition of the present invention can be used as a composition for preparing functional health foods for preventing and treating hypertension and various cardiovascular diseases caused by complications of hypertension. | 2012-08-09 |
| 20120202758 | CORE 2GLCNAC-T INHIBITORS - Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc-T are provided using compounds of the formula I | 2012-08-09 |
| 20120202759 | ISOFLAVONE COMPOSITIONS FOR REDUCING ACCUMULATION OF BODY FAT IN MALE MAMMALS, AND METHODS FOR THEIR USE - Edible compositions useful for weight management in male animals are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites and are particularly useful for reducing or preventing the accumulation of body fat. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones. The compositions and methods are particularly useful for the reduction or prevention of body fat accumulation during periods of excess caloric intake, and preferably have a sparing effect on lean body mass. | 2012-08-09 |
| 20120202760 | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate - This invention relates to enhancing sensitivity of cytotoxic drugs by targeting their interfering mechanisms induced in the tumor microenvironment which lead to drug resistance, using combinatorial therapy with carboxyamidotriazole orotate. Specific doses of cytotoxic drugs are titrated with carboxyamidotriazole orotate to improve the sensitivity and anticancer activity of cytotoxic drugs. | 2012-08-09 |
| 20120202761 | Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt - This invention is in the field of anthracycline family of drugs. More particularly, it concerns converting daunorubicin hydrochloride to an orotate salt and providing methods of improving the tolerability of daunorubicin in animals by reducing the adverse effects and toxicity in noncancerous tissues. Daunorubicin orotate provides a safer treatment for specific types of leukemias and neuroblastomas in adults and in pediatric patients. | 2012-08-09 |
| 20120202762 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES - Methods are provided for using a compound to treat, for example, endothelial dysfunction including vascular abnormalities. More specifically, methods are described for using an oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated in either. | 2012-08-09 |
| 20120202763 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS - Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments. | 2012-08-09 |
| 20120202764 | LOW MOLECULAR WEIGHT PHARMACOLOGICAL ACTIVITY MODULATORS - Claimed are a compound of the general formula (I) and pharmaceutically acceptable salts thereof, where M signifies metal atoms selected independently from the group comprising Pd, Fe, Mn, Co, Ni, Cu, Zn and Mo; R | 2012-08-09 |
| 20120202765 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 2012-08-09 |
| 20120202766 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof. | 2012-08-09 |
| 20120202767 | HYALURONIC ACID BASED MUCOADHESIVE THERAPEUTIC COMPOSITION FOR THE PREVENTION AND TREATMENT OF EPITHELIAL AND MUCOSAL LESIONS OF THE HUMAN BODY - A sucralfate and hyaluronic acid based mucoadhesive composition of very low viscosity and its physiologically acceptable salts for the treatment and prevention of epithelial and mucosal lesions of the human body. | 2012-08-09 |
| 20120202768 | MICROALGAL POLYSACCHARIDE COMPOSITIONS - Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin. | 2012-08-09 |
| 20120202769 | FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R | 2012-08-09 |
| 20120202770 | ANIMAL FEEDS AND VETERINARY COMPOSITIONS - The present invention relates to an animal feed composition comprising protein from the family Fabaceae and protein from the family Asteraceae and to such formulations which also comprise glucan and/or mannan; such feeds finding utility in stabilising or increasing weight in a target animal, particularly fish, as well as in treating ectoparasitic infections, diarrhoea and bowel disease. | 2012-08-09 |
| 20120202771 | THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION DISEASES - Provided is a therapeutic agent for an influenza virus infectious disease, which utilizes an active ingredient derived from a natural product and has an excellent effect. The therapeutic agent for an influenza virus infectious disease includes, as an active ingredient, a β-glucan-containing composition obtained from a culture of a microorganism belonging to | 2012-08-09 |
| 20120202772 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein. | 2012-08-09 |
| 20120202773 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT - A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP | 2012-08-09 |
| 20120202774 | ACYLOXY- AND PHOSPHORYLOXY-BUTADIENE-FE(CO)3 COMPLEXES AS ENZYME-TRIGGERED CO-RELEASING MOLECULES - The present invention provides acyloxy- and phosphoryloxy-butadiene-Fe(CO) | 2012-08-09 |
| 20120202775 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES - Compounds having drug and bio-affecting properties are described herein, including their properties, pharmaceutical compositions and methods of use. In particular, tricyclic aryl or heteroaryl piperazine diamide derivatives that possess unique antiviral activity are set forth. These compounds are useful for the treatment of HIV and AIDS. The compounds herein have the general Formula I: | 2012-08-09 |
| 20120202776 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS - The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use. | 2012-08-09 |
| 20120202777 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents - The present invention is directed to a new class of hydroxamic acid derivatives of Formula I, | 2012-08-09 |
| 20120202778 | USE OF AT LEAST ONE OMEGA-3 FATTY ACID AND OF AT LEAST ONE POLYPHENOL FOR THE ENDOGENOUS SYNTHESIS OF EICOSAPENTANOIC ACID AND DOCOSAHEXANOIC ACID - The present invention relates to the use of at least one fatty acid of the omega-3 group, selected from among α-linolenic acid and stearidonic acid, and of at least one polyphenol as an agent for increasing the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid, for preparing a food, health, or pharmaceutical composition to be administered to a human being or to an animal. | 2012-08-09 |
| 20120202779 | MANAGEMENT OF BREAKTHROUGH BLEEDING IN EXTENDED HORMONAL CONTRACEPTIVE REGIMENS - The present invention relates to a flexible extended use regimen for a hormonal contraceptive useful to manage bleeding problems associated with fixed extended use of hormonal contraceptives and to a pharmaceutical package containing the respective hormonal contraceptive. | 2012-08-09 |
| 20120202780 | CARRIER COMPOSITION - A carrier composition of the present invention comprises a phosphate compound of an electron transfer agent and a relatively high concentration of a polar protic solvent. A biologically active compound may be formulated with a carrier composition of the present invention to provide a formulation. | 2012-08-09 |
| 20120202781 | INDANE DERIVATIVES - The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease. | 2012-08-09 |
| 20120202782 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb). | 2012-08-09 |
| 20120202783 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS - Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 2012-08-09 |
| 20120202784 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2012-08-09 |
| 20120202785 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE - Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2012-08-09 |
| 20120202786 | THERAPEUTIC ISOXAZOLE COMPOUNDS - The invention provides a compound of formula I: | 2012-08-09 |
| 20120202787 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I; | 2012-08-09 |
| 20120202788 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R | 2012-08-09 |
| 20120202789 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - The present invention relates to the use of specific compounds related to the indolocarbazole K252a, for the preparation of pharmaceutical compositions for the treatment of various forms of cancer. | 2012-08-09 |
| 20120202790 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: | 2012-08-09 |
| 20120202791 | Tricyclic and Tetracyclic Systems with Activity on the Central Nervous and Vascular Systems - The present invention relates to chemistry and pharmacy and, in particular, to the production of novel molecular entities, tricyclic and tetracyclic derivatives of benzodiazepine, pyridodiazepine and pyrimidodiazepine type fused with 1,4-dihydropyridine derivatives, having an effect on the central-nervous and vascular systems. Derivatives containing a dihydropyridine ring are used, by means of reactions with compounds of the ortho-phenylenediamine, ortho-diaminopyridine and ortho-diaminopyrimidine type, and also subsequent conversions to some thereof, to obtain tricyclic and tetracyclic derivatives of general formula I-XII that contain a diazepine or diazepinone nucleus fused to a 1,4-dihydropyridine nucleus, in which the A ring is a substituted or unsubstituted benzene, pyridine or pyrimidine ring. These molecular entities exhibit GABAergica and modulating action in the case of calcium channels which can be used in the treatment of cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric and neurological disorders. | 2012-08-09 |
| 20120202792 | Antimicrobial Compounds and Methods of Making and Using the Same - The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and/or reducing the risk of microbial infections in humans and animals. | 2012-08-09 |
